Cargando…
EOLIA trial: the future of extracorporeal membrane oxygenation in acute respiratory distress syndrome therapy?
In the EOLIA trial, early use of ECMO did not significantly improve mortality at 60 days in patients with severe ARDS, but when used as a rescue modality ECMO might help improve survival http://bit.ly/2XOjwSE
Autores principales: | Sameed, Muhammad, Meng, Zhou, Marciniak, Ellen T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717615/ https://www.ncbi.nlm.nih.gov/pubmed/31508163 http://dx.doi.org/10.1183/20734735.0363-2018 |
Ejemplares similares
-
Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19
por: Arikan, Huseyin, et al.
Publicado: (2021) -
Successful application of extracorporeal membrane oxygenation due to pulmonary hemorrhage secondary to granulomatosis with polyangiitis
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2013) -
Extracorporeal membrane oxygenation with right ventricular support in COVID-19 patients with severe acute respiratory distress syndrome
por: Tatooles, Antone J., et al.
Publicado: (2021) -
Acute respiratory distress syndrome in the cardiothoracic patient: State of the art and use of veno-venous extracorporeal membrane oxygenation
por: Copeland, Hannah, et al.
Publicado: (2021) -
Extracorporeal membrane oxygenation for acute respiratory distress syndrome
por: Aokage, Toshiyuki, et al.
Publicado: (2015)